相关实验视频

Updated: May 22, 2025

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

SMAC/DIABLO:一个守护天使在促进抗癌药物诱导的亡

Anuja Mishra¹, Swaroop Kumar Pandey¹

¹Department of Biotechnology, Institute of Applied Sciences &Humanities, GLA University, Mathura, 281406, India.

Current molecular medicine

|May 21, 2025

概括

在许多癌症中,SMAC/Diablo (SMAC) 蛋白质启动了亡,但在许多癌症中过度表达. 它在脂合成中的非亡作用对瘤生长和耐药性至关重要,提供了新的治疗点.

科学领域:

分子生物学分子生物学
癌症生物学癌症生物学
生物化学生物化学

背景情况:

细胞亡是一种关键的细胞过程,在癌症中经常受到失调,导致癌症的进展和耐药性.
SMAC/Diablo (SMAC) 是一种线粒体蛋白质,通过中和亡抑制剂 (IAP) 和激活隙,促进亡.
虽然SMAC在癌症中经常受到下调,但其在各种癌症类型中的过度表达表明了复杂的作用.

研究的目的:

审查SMAC/Diablo在细胞功能中所扮演的双重角色.
探索SMAC过度表达在癌细胞和瘤生长中的意义.
讨论SMAC在癌症药物耐药性方面的非亡性功能的影响.

主要方法:

关于SMAC/Diablo在亡和癌症中的功能研究的文献综述.
对SMAC在调节脂合成中的作用的研究分析.
对SMAC模拟剂和组合疗法的临床数据和临床前研究的审查.

主要成果:

通过对抗IAP和激活caspases,SMAC/Diablo启动了细胞亡.
与其前性功能相反,SMAC在许多癌症中过度表达,包括肺癌,乳腺癌和结肠癌.
过度表达的SMAC对于瘤生长是必不可少的,通过非亡性调节脂合成.
在药物耐药性中,SMAC的作用与其非亡功能有关.

结论:

SMAC/Diablo既表现出促亡的功能,也表现出非亡的功能,而后者对于癌症的进展至关重要.
癌症中SMAC的过度表达突显了它在亡之外的复杂作用,特别是在脂合成中.
针对SMAC的非亡途径是克服癌症药物耐药性的有希望的策略.

关键词:

癌症癌症癌症癌症这是一个SMAC/diablo.灭症 (apoptosis) 是一种死亡的过程.药物耐药性. 药物耐药性.药物目标是药物目标.

更多相关视频

Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells

Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells

Published on: January 29, 2019

Flow Cytometric Analysis of Apoptotic Biomarkers in Actinomycin D-Treated SiHa Cervical Cancer Cells

Flow Cytometric Analysis of Apoptotic Biomarkers in Actinomycin D-Treated SiHa Cervical Cancer Cells

Published on: August 26, 2021

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...